NovaBridge Biosciences (NBP) Income towards Parent Company (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Income towards Parent Company of -$72.9 million for Q4 2025, down 312.02% year-over-year from $34.4 million in Q4 2024, and down 967.05% quarter-over-quarter from -$6.8 million in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Income towards Parent Company (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Income towards Parent Company for 5 consecutive years, with -$72.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Income towards Parent Company fell 312.02% year-over-year to -$72.9 million; the TTM figure through Dec 2025 stood at -$88.3 million (down 421.63% YoY), while the FY2024 annual figure was $27.5 million, up 1560668.18% from the prior year.
- Income towards Parent Company retreated to -$72.9 million in Q4 2025 per NBP's latest filing, from -$6.8 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $34.4 million in Q4 2024 and bottomed at -$72.9 million in Q4 2025.
- Historically, Income towards Parent Company has averaged -$6.1 million across 3 years, with a median of -$1.6 million in 2023.
- Annual changes were most pronounced in 2024 — Income towards Parent Company soared 177.78% — and 2025, when it sank 6115455.56%.
- NovaBridge Biosciences' Income towards Parent Company stood at $90.0 in 2023, then jumped by 38182122.22% to $34.4 million in 2024, then sank by 312.02% to -$72.9 million in 2025.
- Business Quant data shows NBP's Income towards Parent Company at -$72.9 million in Q4 2025, -$6.8 million in Q3 2025, and -$5.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | NovaBridge Biosciences | 199.33 Mn | 199.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -88.34 Mn |
| Sep 30, 2025 | 8.65 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -22.23 Mn |
| Sep 30, 2024 | -250.00 |
| Jun 30, 2024 | -90.00 |
| Mar 31, 2024 | -16.32 Mn |
| Dec 31, 2023 | -162.42 Mn |
| Sep 30, 2023 | -90.00 |
| Jun 30, 2023 | -330.00 |
| Dec 31, 2020 | 160.85 Mn |
| Sep 30, 2020 | 1.77 Mn |
| Dec 31, 2019 | -49.46 Mn |
| Sep 30, 2019 | -35.10 Mn |